Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Altimmune, Inc. (ALT) will report its Q4 and full year 2023 financial results on March 27, 2024, with a business update. A conference call will be held at 8:30 am E.T. on the same day. The call will be webcast live on Altimmune's Investor Relations website, with a replay available for three months.
03/20/2024 - 07:30 AM
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors .
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com .
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter
Investor Contact: reisenstadt@altimmune.com
Media Contact: Danielle.cantey@inizioevoke.com
When will Altimmune report its Q4 and full year 2023 financial results?
Altimmune will report its Q4 and full year 2023 financial results on March 27, 2024.
What time will the conference call be held on March 27, 2024?
The conference call will be held at 8:30 am E.T. on March 27, 2024.
Where can participants access the live webcast of the conference call?
Participants can access the live webcast of the conference call on Altimmune's Investor Relations website at https://ir.altimmune.com/investors.
How long will the replay of the conference call be available?
The replay of the conference call will be available on the Investor Relations website for up to three months.
How can participants register to join the conference call?
Participants can register to join the conference call and receive the dial-in numbers and unique PIN by visiting the provided link.
ALT Rankings
#5342 Ranked by Stock Gains
ALT Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Gaithersburg
About ALT
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
